EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinations

Eirini Tsirvouli, Henri Colyn Bwanika, Ana Martinez Del Val, Liv Thommesen, Astrid Lægreid, Martin Kuiper, Jesper Olsen, Åsmund Flobak

Molecular & Cellular Proteomics · 2026-11 · 101700

DOI: 10.1016/j.mcpro.2026.101700 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-11. Verfasst von Eirini Tsirvouli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, Norwegian University of Science and Technology, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian Un…. Die Arbeit nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted kinase inhibitors often yield transient or incomplete responses because tumour cells buffer pathway blockade through signalling cross-talk, motivating synergistic drug combinations. However, it remains unclear whether synergy typically arises from engaging new signalling programs or from reinforcing the dominant effects of each monotherapy at shared downstream control points. Here we analyse two synergistic inhibitor pairs in AGS gastric adenocarcinoma cells: PI3K inhibition combined with inhibition of either MEK (MAP2K1, MAP2K2) or TAK1 (MAP3K7). Using time-resolved phosphoproteomics and transcriptomics after single-agent and combination treatment, we track signalling and transcriptional rewiring from 30 minutes to 24 h and partition combination responses into monotherapy-like versus combination-specific components. We show that global phosphorylation and gene expression changes under both combinations largely mirror those of the monotherapies, with limited evidence for uniquely engaged kinase programs. Instead, synergy concentrates at pathway convergence nodes, where combined perturbation amplifies downstream regulation of growth and survival circuitry, including transcriptional control through MYC and CREB1. Both combinations produce stronger suppression of MYC-linked proliferative programs and CREB1-associated survival signalling than either single agent, consistent with reinforced constraint on cell-fate decisions. At the transcriptional level, the combinations uniquely repress nucleotide metabolism and aminoacyl-tRNA biosynthesis, consistent with reduced mTOR activity. Together, these results indicate that synergistic growth inhibition can arise primarily from strengthened pathway convergence rather than recruitment of new signalling routes. Our approach provides insights into the molecular mechanisms affected by the PI3Ki-TAK1i and PI3Ki-MEKi combinations and can serve as a flexible framework for dissecting drug combination responses based on multi-omics measurements.

Autor:innen und Institutionen

  • Department of Biology, Norwegian University of Science and Technology, Trondheim, Norway; Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • The Novo Nordisk Foundation Center for Protein Research, University of Copenhagen Denmark, Copenhagen, Denmark.
  • Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; Department of Biomedical Laboratory Science, Norwegian University of Science and Technology, Trondheim, N…
  • Department of Biology, Norwegian University of Science and Technology, Trondheim, Norway.
  • Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway; The Cancer Clinic, St Olav's University Hospital, Trondheim, Norway; Department of Biotechnology and Nano…

Zitieren

APA

Tsirvouli, E., Bwanika, H. C., Martinez Del Val, A., Thommesen, L., Lægreid, A., Kuiper, M., Olsen, J., & Flobak, Å. (2026). Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinations. Molecular & Cellular Proteomics, 101700. https://doi.org/10.1016/j.mcpro.2026.101700

Vancouver

Tsirvouli E, Bwanika HC, Martinez Del Val A, Thommesen L, Lægreid A, Kuiper M, et al. Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinations. Molecular & Cellular Proteomics. 2026:101700. doi:10.1016/j.mcpro.2026.101700

BibTeX
@article{Tsirvouli2026,
  author = {Tsirvouli, Eirini and Bwanika, Henri Colyn and Martinez Del Val, Ana and Thommesen, Liv and Lægreid, Astrid and Kuiper, Martin and Olsen, Jesper and Flobak, Åsmund},
  title = {Deciphering molecular mechanisms of synergistic growth reduction in kinase inhibitor combinations},
  journal = {Molecular & Cellular Proteomics},
  year = {2026},
  pages = {101700},
  doi = {10.1016/j.mcpro.2026.101700}
}
Kostenlos starten →